Sorafenib and vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) are among the most commonly used treatment options for various cancers, especially renal and hepatocellular carcinoma [1,2]. The gene discussed is VEGFA; the disease is cancer.